70284 Federal Register / Vol. 69, No. 232 / Friday, December 3, 2004 / Notices 

Register pursuant to section 6(b) of the 

Act on August 18, 2004 (69 FR 51329).

Dorothy B. Fountain, 

Deputy Director of Operations, Antitrust 

Division.

[FR Doc. 04–26614 Filed 12–2–04; 8:45 am] 

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division 

Notice Pursuant to the National 

Cooperative Research and Production 

Act of 1993—VSI Alliance 

Notice is hereby given that, on 

October 8, 2004, pursuant to section 6(a) 

of the National Cooperative Research 

and Production Act of 1993, 15 U.S.C. 

4301 et seq. (‘‘the Act’’), VSI Alliance 

has filed written notifications 

simultaneously with the Attorney 

General and the Federal Trade 

Commission disclosing changes in its 

membership status. The notifications 

were filed for the purpose of extending 

the Act’s provisions limiting the 

recovery of antitrust plaintiffs to actual 

damages under specified circumstances. 

Specifically, Microelectronics Research 

Institute ‘‘PROGRESS’’, Moscow, 

RUSSIA; and David Gardner (individual 

member), Round Rock, TX have been 

added as parties to this venture. 

Also, Alcatel, Edegem, BELGIUM; Bob 

Altizer (individual member), Phoenix, 

AZ; Guy Bois (individual member), 

Montreal, Quebec, CANADA; Annette 

Bunker (individual member), Salt Lake 

City, UT; Ramesh Chandra (individual 

member), San Diego, CA; Edoardo 

Charbon (individual member), Berkeley, 

CA; Lee Dilley (individual member), 

Doylestown, PA; Dolphin Technology, 

San Jose, CA; GDA Technology, 

Karnatake, INDIA; Qun Ge (individual 

member), Shanghai, PEOPLE’S 

REPUBLIC OF CHINA; David 

Greenstein (individual member), 

Cupertino, CA; Carolyn Hayden, 

Ottawa, Ontario, CANADA; HD Labs, 

Yokohama, JAPAN; Robert Helt 

(individual member), Moraga, CA; IPTC 

Corporation, Yokohama, JAPAN; Gerald 

Keeler (individual member), San 

Francisco, CA; Alfred Kwok (individual 

member), San Jose, CA; Kun-Bin Lee 

(individual member), Hsinchu, 

TAIWAN; Samy Makar (individual 

member), Fremont, CA; 

Microelectronics Center of Harbin 

Institute of Technology, Harbin, 

PEOPLE’S REPUBLIC OF CHINA; 

Seijiro Moriyama (individual member), 

Kohoku-ku, JAPAN; Miodrag Potkonjak 

(individual member), Los Angeles, CA; 

Hardy Pottinger (individual member), 

Rolla, MO; Gang Qu (individual 

member), College Park, MD; Alberto 

Sangiovanni-Vincentelli (individual 

member), Berkeley, CA; Richard 

Stolzman (individual member), 

Campbell, CA; Patrick Sullivan 

(individual member), Palo Alto, CA; 

James Tobias (individual member), San 

Jose, CA; Kumar Venkatramani 

(individual member), Saratoga, CA; Joe 

Villella (individual member), Palo Alto, 

CA; and Kurt Woodland (individual 

member), Morgan Hill, CA have been 

dropped as parties to this venture. 

No other changes have been made in 

either the membership or planned 

activity of the group research project 

remains open, and VSI Alliance intends 

to file additional written notification 

disclosing all changes in membership. 

On November 29, 1996, VSI Aliance 

filed its original notification pursuant to 

section 6(a) of the Act. The Department 

of Justice published a notice in the 

Federal Register pursuant to Section 

6(b) of the Act on March 4, 1997 (62 FR 

9812). 

The last notification was filed with 

the Department on July 12, 2004. A 

notice was published in the Federal 

Register pursuant to section 6(b) of the 

Act on August 18, 2004 (69 FR 51330).

Dorothy B. Fountain, 

Deputy Director of Operations, Antitrust 

Division.

[FR Doc. 04–26617 Filed 12–2–04; 8:45 am] 

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration 

[Docket No. DEA–259P] 

Controlled Substances: Proposed 

Aggregate Production Quotas for 2005

AGENCY: Drug Enforcement 

Administration (DEA), Justice.

ACTION: Notice of proposed year 2005 

aggregate production quotas. 

SUMMARY: This notice proposes initial 

year 2005 aggregate production quotas 

for controlled substances in Schedules I 

and II of the Controlled Substances Act 

(CSA).

DATES: Comments or objections must be 

received on or before December 27, 

2004.

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–259P’’ on all written and 

electronic correspondence. Written 

comments being sent via regular mail 

should be sent to the Deputy Assistant 

Administrator, Office of Diversion 

Control, Drug Enforcement 

Administration, Washington, DC 20537, 

Attention: DEA Federal Register 

Representative/ODL. Written comments 

sent via express mail should be sent to 

DEA Headquarters, Attention: DEA 

Federal Register Representative/ODL, 

2401 Jefferson-Davis Highway, 

Alexandria, VA 22301. Comments may 

be directly sent to DEA electronically by 

sending an electronic message to 

dea.diversion.policy@usdoj.gov. 

Comments may also be sent 

electronically through http://

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the

http://www.regulations.gov Web site. 

DEA will accept attachments to 

electronic comments in Microsoft Word, 

WordPerfect, Adobe PDF, or Excel file 

formats only. DEA will not accept any 

file format other than those specifically 

listed here.

FOR FURTHER INFORMATION CONTACT:

Christine A. Sannerud, Ph.D., Chief, 

Drug and Chemical Evaluation Section, 

Drug Enforcement Administration, 

Washington, DC 20537, Telephone: 

(202) 307–7183.

SUPPLEMENTARY INFORMATION: Section 

306 of the CSA (21 U.S.C. 826) requires 

that the Attorney General establish 

aggregate production quotas for each 

basic class of controlled substance listed 

in Schedules I and II. This 

responsibility has been delegated to the 

Administrator of the DEA by Section 

0.100 of Title 28 of the Code of Federal 

Regulations. The Administrator, in turn, 

has redelegated this function to the 

Deputy Administrator, pursuant to 

Section 0.104 of Title 28 of the Code of 

Federal Regulations. 

The proposed year 2005 aggregate 

production quotas represent those 

quantities of controlled substances that 

may be produced in the United States in 

2005 to provide adequate supplies of 

each substance for: the estimated 

medical, scientific, research, and 

industrial needs of the United States; 

lawful export requirements; and the 

establishment and maintenance of 

reserve stocks. These quotas do not 

include imports of controlled 

substances for use in industrial 

processes. 

In determining the proposed year 

2005 aggregate production quotas, the 

Deputy Administrator considered the 

following factors: total actual 2003 and 

estimated 2004 and 2005 net disposals 

of each substance by all manufacturers; 

estimates of 2004 year-end inventories 

of each substance and of any substance 

manufactured from it and trends in 

accumulation of such inventories;